Goserelin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

For patient information, click here.

Goserelin

Clinical data
Synonyms	D-Ser(But)6Azgly10LHRH
Pregnancy category	D (3.6mg) / X (10.8mg) (USA)
Routes of administration	implant
ATC code	L02AE03 (WHO)
Legal status
Legal status	In general: ℞ (Prescription only)
Pharmacokinetic data
Protein binding	27.3%
Elimination half-life	4-5 hours
Excretion	renal
Identifiers
IUPAC name N-[1-[[1-[[1-[[1-[[1-[[1-[[1-[2- [(carbamoylamino)carbamoyl]pyrrolidin-1-yl]- 5-(diaminomethylideneamino)-1-oxo -pentan-2-yl]carbamoyl]-3-methyl- butyl]carbamoyl]-2-tert-butoxy- ethyl]carbamoyl]-2-(4-hydroxyphenyl) ethyl]carbamoyl]-2-hydroxy-ethyl] carbamoyl]-2-(1H-indol-3-yl)ethyl] carbamoyl]-2-(3H-imidazol-4-yl)ethyl]- 5-oxo-pyrrolidine-2-carboxamide
CAS Number	65807-02-5
PubChem CID	47725
DrugBank	BTD00113
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C59H84N18O14
Molar mass	1269.410 g/mol

WikiDoc Resources for Goserelin
Articles
Most recent articles on Goserelin Most cited articles on Goserelin Review articles on Goserelin Articles on Goserelin in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Goserelin Images of Goserelin Photos of Goserelin Podcasts & MP3s on Goserelin Videos on Goserelin
Evidence Based Medicine
Cochrane Collaboration on Goserelin Bandolier on Goserelin TRIP on Goserelin
Clinical Trials
Ongoing Trials on Goserelin at Clinical Trials.gov Trial results on Goserelin Clinical Trials on Goserelin at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Goserelin NICE Guidance on Goserelin NHS PRODIGY Guidance FDA on Goserelin CDC on Goserelin
Books
Books on Goserelin
News
Goserelin in the news Be alerted to news on Goserelin News trends on Goserelin
Commentary
Blogs on Goserelin
Definitions
Definitions of Goserelin
Patient Resources / Community
Patient resources on Goserelin Discussion groups on Goserelin Patient Handouts on Goserelin Directions to Hospitals Treating Goserelin Risk calculators and risk factors for Goserelin
Healthcare Provider Resources
Symptoms of Goserelin Causes & Risk Factors for Goserelin Diagnostic studies for Goserelin Treatment of Goserelin
Continuing Medical Education (CME)
CME Programs on Goserelin
International
Goserelin en Espanol Goserelin en Francais
Business
Goserelin in the Marketplace Patents on Goserelin
Experimental / Informatics
List of terms related to Goserelin

Overview

Goserelin Acetate is an injectable gonadotropin releasing hormone super-agonist (GnRH agonist). It stops the production of sex hormones (testosterone and oestrogen).

Goserelin Acetate is marketed by AstraZeneca with the brand name Zoladex. It was first launched in 1987 and is currently the second-largest selling GnRH analogue in the world. It is currently available in more than one hundred markets.

Zoladex 3.6 mg subcutaneous monthly biodegradable implant was first approved by the FDA on November 3, 1989 for treatment of prostate cancer, a 10.8 mg subcutaneous 3-month biodegradable implant and other indications were subsequently approved.

Pharmacokinetics

Goserelin is a synthetic analogue of a naturally occurring luteinising-hormone releasing hormone (LHRH). Bioavailability is almost complete. Gosereline is poorly protein bound and has a serum elimination half-life of two to four hours in patients with normal renal function. The half-life increases with patients with impaired renal function. There is no significant change in pharmacokinetics in subjects with hepatic failure. After administration, peak serum concentrations are reached in about two hours. It rapidly binds to the LHRH receptor cells in the pituitary gland thus leading to an initial increase in production of luteinizing hormone and thus leading to an initial increase in the production of corresponding sex hormones. This initial Flare may be treated by co-prescribing/co-administering Casodex (Bicalutamide) or similar medication. Eventually, after a period of about 14-21 days, production of LH is greatly reduced due to receptor downregulation, and sex hormones are generally reduced to castrate levels.

Indications

Goserelin Acetate is used to treat hormone-sensitive cancers of the prostate and breast (in pre-/perimenopausal women) and some benign gynaecological disorders (endometriosis, uterine fibroids and endometrial thinning). In addition, goserelin is used in assisted reproduction and in the treatment of precocious puberty. The syringe applicator comes with a protective sleeve, called the SafeSystem, to reduce and prevent needlestick injuries to administering healthcare professionals.

It is available as a 1-month depot and a long-acting 3-month depot. Both depots are used for the treatment of prostate cancer, endometriosis and uterine fibroids but only the 1-month depot is approved for breast cancer, endometrial thinning and assisted reproduction.

NOTE: The above license is probably from the USA. It should be noted that licensed indications may vary from country to country. For example, in the UK the 1-month depot is licensed for prostate cancer, endometriosis, uterine fibroids, breast cancer, endometrial thinning and assisted reproduction, and not as above. You are advised to consult a Healthcare Professional or your local regulatory authorities if you need more information on your local license for this product.

Side effects

Goserelin Acetate may cause a temporary increase in bone pain and symptoms of prostatic cancer during the first few weeks of treatment. As the body adjusts to the medication, the symptoms will disappear. Goserelin may cause hot flushes, headache, stomach upset, difficulty urinating (isolated cases), weight gain, swelling and tenderness of breasts (infrequent), decreased erections, reduced sexual desire. Bone pain can be managed symptomatically, and decreased libido can be treated by Levitra (Vardenifil) or other similar oral therapies.

Interactions

No known interaction with other medicinal products.

Effects on ability to drive and operate machinery

There is no evidence that Goserelin Acetate results in impairment of these activities.

External links

• One man's experience of prostate cancer treatment using goserelin - BBC News